Showing results (111-120 of 172) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|May 7, 2013
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumorsR Salazar, H Cortés-Funes, E Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 31, 2011
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancerN Starling, F Vázquez-Mazón, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressionR Obermannová, E Van Cutsem, T Yoshino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsJ-C Soria, F DeBraud, R Bahleda, et al.
Oncogene|June 6, 2017
Pancreatic cancer heterogeneity and response to Mek inhibitionK Pedersen, F Bilal, C Bernadó Morales, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2018
Early evolutionary divergence between papillary and anaplastic thyroid cancersJ Capdevila, R Mayor, F M Mancuso, et al.
ESMO Open|June 2, 2022
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRCS Kopetz, A Grothey, E Van Cutsem, et al.
ESMO Open|September 21, 2021
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I studyR Bordonaro, A Calvo, A Auriemma, et al.
Oncogene|June 9, 2016
Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoterX Qu, T Sandmann, H Frierson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2023
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatmentsJ Ros, J Matito, G Villacampa, et al.
Pageof 18